{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:33:46Z","timestamp":1767825226570,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T00:00:00Z","timestamp":1310601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>\n            <jats:bold>Background <\/jats:bold> The extrafine\u2010particle formulation of hydrofluoroalkane\u2013beclometasone (EF HFA\u2013BDP; Qvar<jats:sup>\u00ae<\/jats:sup>) demonstrates improved total and small airway deposition compared with large\u2010particle chlorofluorocarbon (CFC)\u2013BDP. In some short\u2010term studies, EF HFA\u2013BDP provides greater effects on lung function than CFC\u2013BDP, and hence is recommended to be prescribed at a lower dose, but whether there are differences in asthma outcomes during long\u2010term treatment is unknown.<\/jats:p><jats:p>\n            <jats:bold>Objective <\/jats:bold> To compare the effectiveness of EF HFA\u2013BDP vs. CFC\u2013BDP over 1 year.<\/jats:p><jats:p>\n            <jats:bold>Methods <\/jats:bold> This retrospective matched cohort study examined outcomes in a large primary care database for patients aged 5\u201360 years with asthma receiving their first inhaled corticosteroid (ICS) prescription (initiation population) or first ICS dose increase (step\u2010up population) by a pressurized metered\u2010dose inhaler (pMDI) as EF HFA\u2013BDP or CFC\u2013BDP. Patients were matched on baseline demographic and asthma severity measures in EF HFA\u2013BDP:CFC\u2013BDP ratios of 1\u2003:\u20033 and 1\u2003:\u20032 for initiation and step\u2010up populations, respectively. Step\u2010up patients were matched also on ICS dose during a baseline year. Co\u2010primary endpoints were asthma control (composite measure comprising no recorded hospital attendance for asthma, oral corticosteroids, or antibiotics for lower respiratory infection) and exacerbation rate during the outcome year.<\/jats:p><jats:p>\n            <jats:bold>Results <\/jats:bold> For the initiation population (EF HFA\u2013BDP <jats:italic>n<\/jats:italic>=2882; CFC\u2013BDP <jats:italic>n<\/jats:italic>=8646), adjusted odds of achieving asthma control with EF HFA\u2013BDP vs. CFC\u2013BDP was 1.15 (95% CI 1.02\u20131.28). For the step\u2010up population (<jats:italic>n<\/jats:italic>=258 and 516), adjusted odds of asthma control with EF HFA\u2013BDP was 1.72 (95% CI 1.14\u20132.56). EF HFA\u2013BDP was prescribed at a median dose half that of CFC\u2013BDP.<\/jats:p><jats:p>\n            <jats:bold>Conclusion and Clinical Relevance <\/jats:bold> During 1 year after initiating or stepping up ICS therapy by pMDI, patients who received EF HFA\u2013BDP were more likely to achieve asthma control than those receiving CFC\u2013BDP. These findings suggest that ICS formulation, particle size, and deposition characteristics play important roles in real\u2010life effectiveness of asthma therapy. This study shows that an EF\u2010particle formulation of beclometasone can be used at half the dose of the large\u2010particle formulation with at least as good clinical outcomes.<\/jats:p><jats:p>\n            <jats:italic>Cite this as<\/jats:italic>: N. Barnes, D. Price, G. Colice, A. Chisholm, P. Dorinsky, E. V. Hillyer, A. Burden, A. J. Lee, R. J. Martin, N. Roche, J. von Ziegenweidt and E. Israel, <jats:italic>Clinical &amp; Experimental Allergy<\/jats:italic>, 2011 (41) 1521\u20131532.<\/jats:p>","DOI":"10.1111\/j.1365-2222.2011.03820.x","type":"journal-article","created":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T06:20:27Z","timestamp":1310624427000},"page":"1521-1532","source":"Crossref","is-referenced-by-count":57,"title":["Asthma control with extrafine\u2010particle hydrofluoroalkane\u2013beclometasone vs. large\u2010particle chlorofluorocarbon\u2013beclometasone: a real\u2010world observational study"],"prefix":"10.1111","volume":"41","author":[{"given":"N.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Colice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dorinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. V.","family":"Hillyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Burden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"von Ziegenweidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,14]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"MHRA. Press release: Medicines regulator informs healthcare professionals about prescribing UK beclometasone dipropionate CFC\u2010free inhalers for asthma. Available athttp:\/\/www.cliniclue.com\/software(accessed 18 June 2011)."},{"key":"e_1_2_6_3_2","unstructured":"British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. A national clinical guideline May 2008 Revised June 2009. Available athttp:\/\/www.mhra.gov.uk\/NewsCentre\/Pressreleases\/CON2024437(accessed 18 June 2011)."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2008.05.0013"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.111582"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/jam.2005.18.379"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12061346"},{"key":"e_1_2_6_8_2","first-page":"510","article-title":"Lung deposition of hydrofluoroalkane\u2010134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone","volume":"122","author":"Leach CL","year":"2002","journal-title":"a cross-over study in healthy volunteers"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.3.9608058"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10020292"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.2.9705036"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(98)90214-1"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.2.343"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70016-3"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.03.026"},{"key":"e_1_2_6_16_2","first-page":"219","article-title":"External validity of randomised controlled trials in asthma","volume":"62","author":"Travers J","year":"2007","journal-title":"to whom do the results of the trials apply?"},{"key":"e_1_2_6_17_2","first-page":"1237","article-title":"Choosing inhaler devices for people with asthma","volume":"104","author":"Haughney J","year":"2010","journal-title":"current knowledge and outstanding research needs"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1155\/2004\/823084"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62905-5"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.6.1824"},{"key":"e_1_2_6_21_2","first-page":"511","article-title":"Prescribing practices and asthma control with hydrofluoroalkane\u2013beclomethasone and fluticasone","volume":"126","author":"Price D","year":"2010","journal-title":"a real-world observational study"},{"key":"e_1_2_6_22_2","unstructured":"General Practice Research Database. Available athttp:\/\/www.sign.ac.uk\/guidelines\/fulltext\/101\/index.html(accessed 18 June 2011)."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.6.445"},{"key":"e_1_2_6_24_2","first-page":"413","article-title":"Use of the General Practice Research Database (GPRD) for respiratory epidemiology","volume":"54","author":"Hansell A","year":"1999","journal-title":"a comparison with the 4th Morbidity Survey in General Practice (MSGP4)"},{"key":"e_1_2_6_25_2","first-page":"373","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies","volume":"40","author":"Charlson ME","year":"1987","journal-title":"development and validation"},{"key":"e_1_2_6_26_2","unstructured":"Communities and Local Government. Indices of deprivation. Available athttp:\/\/www.gprd.com\/home\/default.asp\/+\/http:\/\/webarchive.nationalarchives.gov.uk(accessed 18 June 2011)."},{"key":"e_1_2_6_27_2","first-page":"59","article-title":"An official American Thoracic Society\/European Respiratory Society statement","volume":"180","author":"Reddel HK","year":"2009","journal-title":"asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice"},{"key":"e_1_2_6_28_2","unstructured":"Research in Real Life: Standard Operating Procedures. Available athttp:\/\/www.communities.gov.uk\/communities\/neighbourhoodrenewal\/deprivation\/(accessed 18 June 2011)."},{"key":"e_1_2_6_29_2","first-page":"S258","article-title":"Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways","volume":"104","author":"Goldin JG","year":"1999","journal-title":"assessment with functional helical thin-section computed tomography"},{"key":"e_1_2_6_30_2","first-page":"257","article-title":"Hydrofluoroalkane\u2010134A beclomethasone or chlorofluorocarbon fluticasone","volume":"42","author":"Thongngarm T","year":"2005","journal-title":"effect on small airways in poorly controlled asthma"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.04.056"},{"key":"e_1_2_6_32_2","first-page":"326","article-title":"Effect of inhaled corticosteroids on small airways in asthma","volume":"22","author":"Yamaguchi M","year":"2009","journal-title":"investigation using impulse oscillometry"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.6.9906075"},{"key":"e_1_2_6_34_2","first-page":"394","article-title":"Lung function in adults with stable but severe asthma","volume":"104","author":"Sorkness RL","year":"2008","journal-title":"air trapping and incomplete reversal of obstruction with bronchodilation"},{"key":"e_1_2_6_35_2","first-page":"e1104","article-title":"Antibiotic treatment of wheezing in children with asthma","volume":"117","author":"Kozyrskyj AL","year":"2006","journal-title":"what is the practice?"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.2008.00167.x"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.2011.03820.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.2011.03820.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:34:55Z","timestamp":1695512095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.2011.03820.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,14]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1111\/j.1365-2222.2011.03820.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.2011.03820.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,14]]}}}